NCT01887353View on ClinicalTrials.gov

The Use of Ranolazine for Atrial Fibrillation and Diastolic Heart Failure

PHASE2TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions
Atrial FibrillationHeart Failure
Interventions
DRUG

Ranolazine

Patients will take ranolazine 1000 mg tablets twice daily

DRUG

Placebo

Placebo pill manufactured to mimic ranolazine 1000 mg tablets. Patients will be instructed to take two pills a day.

Trial Locations (1)

84107-5701

Intermountain Medical Center, Murray

Sponsors

Collaborators (1)

Gilead Sciences
All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

lead

Intermountain Health Care, Inc.

OTHER

NCT01887353 - The Use of Ranolazine for Atrial Fibrillation and Diastolic Heart Failure | Biotech Hunter | Biotech Hunter